Investor Presentaiton

41 Investor presentation Full year 2022 Novo Nordisk has a leadership position within the growing diabetes market Novo NordiskⓇ Global diabetes market by treatment class¹ Novo Nordisk remains global diabetes value market leader DKK billion 40% Market CAGR: 4% 400 Novo Nordisk market share and share of growth 30% 300 60% 32% 40% CAGR: -3% 200 CAGR: 16% 20% CAGR: -4% 20% 38% 36% 32% 29% 100 10% CAGR: 19% 0 0% 0% 2017 2018 2019 2020 2021 Nov Nov Nov Nov 2012 2022 2019 2022 GLP-1 Insulin SGLT-2i DPP-4i Novo Nordisk -Takeda NN market share -Sanofi Merck Astra Zeneca -J&J 1 Data is based on company reported sales from Sanofi, Eli Lilly, AstraZeneca, GSK, Novartis, Johnson & Johnson, and Merck. Data does not include generic metformin, sulphonylureas or thiazolidinedione BI: Boehringer Ingelheim; J&J: Johnson & Johnson; NN: Novo Nordisk Source: IQVIA MAT, Nov 2022 value figures Note: IQVIA data can be inflated due to use of list prices in the US -NN share of growth Market growth (right axis) -NN growth (right axis) Eli Lilly BI Novartis

View entire presentation